Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefpodoxime proxetil + lactic acid bacillus
- Development stage
- Unknown
- Lead developer
- Thrift Pharmaceuticals
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Creo-Plus is a fixed-dose combination tablet containing cefpodoxime proxetil, a third-generation cephalosporin antibiotic, and Lactic Acid Bacillus, a probiotic. Cefpodoxime proxetil is a prodrug that is converted in vivo to active cefpodoxime, which exerts bactericidal activity by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall synthesis. Lactic Acid Bacillus is co-formulated as a probiotic to help restore and maintain the natural balance of gut microbiota, thereby preventing or mitigating antibiotic-associated diarrhea (AAD) and other gastrointestinal side effects commonly caused by broad-spectrum antibiotic therapy. Creo-Plus is approved and marketed for the treatment of various susceptible bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media.
- Brand names
- Creo-Plus
- Other names
- cefpodoxime + lactic acid bacilluscefpodoxime and lactic acid bacilluscefpodoxime proxetil and lactic acid bacilluscefpodoxime proxetil with lactic acid bacilluscefpodoxime with lactic acid bacillus
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on cefpodoxime proxetil + lactic acid bacillus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefpodoxime proxetil + lactic acid bacillus.